Charles River Laboratories International (CRL) : During the past 4 weeks, traders have been relatively bearish on Charles River Laboratories International (CRL), hence the stock is down -5.11% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.28% relative to the S&P 500. The 4-week change in the price of the stock is -4.75% and the stock has fallen -0.31% in the past 1 week.
Charles River Laboratories International, Inc. has dropped 2.28% during the last 3-month period . Year-to-Date the stock performance stands at 2.82%. The stock has recorded a 20-day Moving Average of 3.22% and the 50-Day Moving Average is 2%.
Charles River Laboratories International (NYSE:CRL): The stock opened at $83.24 on Friday but the bulls could not build on the opening and the stock topped out at $83.39 for the day. The stock traded down to $82.38 during the day, due to lack of any buying support eventually closed down at $82.66 with a loss of -0.84% for the day. The stock had closed at $83.36 on the previous day. The total traded volume was 199,704 shares.
Also, Citigroup maintains its rating on Charles River Laboratories International (NYSE:CRL). The global brokerage major raises the current price target from $85 per share to $90 per share. Analysts at the Citigroup have a current rating of Neutral on the shares. The rating by the firm was issued on August 4, 2016.
Charles River Laboratories International, Inc. is a full service, early stage contract research company. The Company offers research models for the research and development of new drugs, devices and therapies. It develops a portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP that support the clients from target identification through preclinical development. The Company operates through three segments: Research Models and Services (RMS), which supplies research models to the drug development industry; Discovery and Safety Assessment (DSA), which provides services that enables the clients to outsource their drug discovery research, critical, regulatory-required safety assessment testing and related drug discovery and development activities, and Manufacturing Support (Manufacturing), which is involved in the production and release of products manufactured by the clients.